What was recalled
This page synthesizes the bromelain inclusion framework in commercial pet food and pet supplements. Bromelain is a complex of proteolytic enzymes extracted from pineapple plants (Ananas comosus), with "stem bromelain" being the dominant commercial form. The enzyme complex contains primarily cysteine proteases (catalyzing peptide bond hydrolysis through a cysteine residue at the active site, in contrast to serine proteases like trypsin and chymotrypsin or aspartic proteases like pepsin). Commercial bromelain preparations have proteolytic activity measured in GDU (gelatin digesting units) or MCU (milk clotting units), with typical commercial preparations standardized to 2,000-2,400 GDU/g or equivalent activity. Bromelain has been the subject of pharmacological research since the 1950s, with documented mechanisms including direct proteolytic activity (proteolysis of dietary protein in the small intestine when administered orally without enteric coating, plus local fibrinolytic and anti-inflammatory effects in topical applications), indirect anti-inflammatory effect (modulation of bradykinin, prostaglandin, and inflammatory mediator metabolism in tissue), fibrinolytic effect (modest plasmin activation and fibrin degradation), and immunomodulatory effect (T-cell modulation in some studies).
The oral absorption challenge for bromelain is the central structural concern. Bromelain is a protein (the active enzyme is approximately 33 kDa molecular weight) and is denatured by gastric acid at the typical stomach pH of 1.5-3.5, which produces irreversible structural unfolding and loss of catalytic activity. Bromelain that survives gastric transit (limited fraction without enteric protection) reaches the small intestine and produces local proteolytic activity on dietary protein (which provides modest digestive-aid effect, particularly for high-protein meals) but is also further degraded by intestinal proteases including trypsin and chymotrypsin. Systemic absorption of intact bromelain through the small intestine is thought to be possible at low percentage (estimates 0.1-3% in various studies) through transcytotic transport mechanisms, but the bulk of orally administered free bromelain is degraded before reaching systemic circulation.
Enteric-coated bromelain formulations protect the enzyme through the stomach to the small intestine, where pH-shift release at intestinal pH (6-7.5) enables intact bromelain delivery to the absorption site. Enteric coating substantially increases the absorbed-bromelain fraction, with studies documenting 3-10x bioavailability improvement compared to unprotected bromelain. Most pet supplement bromelain inclusion does NOT use enteric coating, which limits the absorbed bromelain dose and therefore the systemic anti-inflammatory effect. Pet food bromelain inclusion further faces the additional challenge that extrusion and retort processing can themselves denature bromelain through high-temperature exposure, although low-temperature processing methods (baked kibble, freeze-dried) better preserve enzymatic activity.
Why it was recalled
The structural marketing-evidence-gap concern has three layers. Layer one — enteric-coating requirement for systemic absorption is rarely addressed in pet food: commercial pet food bromelain inclusion typically uses unprotected bromelain powder added to formulation; the inclusion provides limited systemic anti-inflammatory effect because gastric acid denatures most of the orally administered enzyme before it reaches the absorption site. Pet supplement bromelain formulations may include enteric coating but many do not, with the same limitation. The mechanistic anti-inflammatory claims in marketing positioning therefore rest primarily on the fraction of bromelain that survives gastric transit and reaches the small intestine, which is a small percentage of total administered dose without enteric protection.
Layer two — local proteolytic activity is a different mechanism than systemic anti-inflammatory effect: the bromelain that reaches the small intestine without enteric coating does produce local proteolytic activity on dietary protein, which functions as a modest digestive aid. This effect is real and reproducible but is different from the systemic anti-inflammatory effect that marketing positioning often emphasizes. The digestive-aid mechanism is most relevant for high-protein meals and may produce modest benefit for pets with documented protein-digestion limitations (exocrine pancreatic insufficiency, chronic enteropathy with maldigestion), but the framework parallels concerns about probiotic strain viability documented in our probiotic strain viability controversy page — the marketing claim and the functional mechanism do not always align.
Layer three — companion-animal controlled-trial evidence is limited: the canine and feline controlled-trial literature on therapeutic bromelain supplementation is sparse. Veterinary clinical use for adjunctive joint support, allergy support, and digestive support exists at the level of complementary-medicine practice rather than evidence-supported guideline. The translation from human osteoarthritis trial evidence (mixed results) and topical-application clinical evidence (NexoBrid burn debridement) to companion-animal therapeutic recommendation requires more controlled-trial work. Brands marketing bromelain inclusion for canine joint, allergy, or digestive support are operating ahead of the companion-animal evidence base, with mechanistic plausibility but limited direct clinical demonstration.
Health risks for your pet
Bromelain at typical pet food and pet supplement inclusion rates is generally well-tolerated and safe for dogs and cats. The mechanistic concerns relevant at higher doses include modest antiplatelet and fibrinolytic effect (relevant for pets on anticoagulant therapy or scheduled for surgical procedures with bleeding risk), rare allergic reaction in pets sensitized to pineapple proteins, theoretical drug-interaction concern with antibiotics (bromelain can enhance the bioavailability of some antibiotics; clinically relevant cases are uncommon), and rare gastrointestinal irritation at very high oral doses. At typical pet inclusion rates, none of these reaches clinically significant magnitude.
The antiplatelet and fibrinolytic effects are dose-dependent and are most relevant for pharmacologic-dose human supplementation (typically 500-2000 mg bromelain daily delivering 1000-4800 GDU). Pet supplement bromelain inclusion at typical rates (50-500 mg daily for medium-size dogs) rarely produces clinically significant antiplatelet effect, but pets scheduled for surgical procedures should typically discontinue bromelain supplementation 7-14 days before surgery as a precaution under veterinary guidance.
What to do if you bought affected product
Pet owners can interpret bromelain pet food and supplement inclusion appropriately through several practical approaches: (1) look for enteric-coated formulations if the marketing positioning emphasizes systemic anti-inflammatory effect; unprotected bromelain inclusion delivers limited systemic effect because gastric acid denatures the enzyme before absorption; (2) understand that local proteolytic activity is different from systemic anti-inflammatory effect — unprotected bromelain in pet food provides modest digestive-aid effect on dietary protein in the small intestine, which is real but different from the systemic mechanism the marketing positioning often emphasizes; (3) for diagnosed osteoarthritis or inflammatory conditions, work with your veterinarian on appropriate pharmaceutical and nutraceutical interventions (NSAIDs, joint-specific therapeutic diets, documented bioavailability nutraceuticals) rather than relying on pet food or supplement bromelain as primary therapy; (4) watch for drug interactions if your pet is on anticoagulant therapy or scheduled for surgical procedures; typical preoperative recommendation is to discontinue bromelain supplementation 7-14 days before surgery; (5) for pets with documented protein-digestion limitations (exocrine pancreatic insufficiency, chronic enteropathy with maldigestion), enzymatic digestive aids including bromelain may provide modest adjunctive benefit under veterinary guidance; coordinate with the prescribing veterinarian; (6) cross-check brand claims — brands marketing therapeutic-tier systemic anti-inflammatory benefit from unprotected bromelain inclusion at typical pet food rates are misrepresenting expected effect magnitude.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 does not currently differentiate bromelain inclusion per our published methodology, since pet food inclusion rates and enteric-coating framework are typically sub-therapeutic for systemic effect. The marketing-evidence-gap framework parallels concerns documented across CLA, CoQ10, phosphatidylserine, milk thistle, ginger, turmeric, quercetin, and other supplementation-framework controversy pages. Future rubric extension under consideration: brands disclosing bromelain inclusion rate with enteric-coating formulation and documented therapeutic-dose calibration would warrant scoring consideration; aggregate "with bromelain" marketing claims without enteric-coating disclosure would not. For now, our recommendation: appreciate bromelain inclusion as a digestive-aid and marketing-claim component, do not expect systemic anti-inflammatory effect at typical pet food inclusion rates without enteric coating, and work with your veterinarian on appropriate pharmaceutical interventions for diagnosed inflammatory or joint concerns.